For biologic-experienced patients hospitalized with acute severe ulcerative colitis, off-label, high-intensity doses of tofacitinib (Xeljanz) given with intravenous corticosteroids may have reduced ...

SAN DIEGO, CA—Changing directly from adalimumab to tofacitinib sustained clinical response and improved ACR response rates in patients with rheumatoid arthritis, an open-label extension study ...

Oral tofacitinib (Xeljanz), a JAK inhibitor, helped regrow hair in three quarters of pediatric patients with alopecia areata (AA) in a small study conducted at the University of Colorado and published ...

Please provide your email address to receive an email when new articles are posted on . Efficacy was similar between patients on tofacitinib and those who switched from adalimumab. Switching from ...

Twice-Daily Tofacitinib Shows Sustained Efficacy Over 5 Years in RA Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension ...

The appraisal committee (section 5) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

Please provide your email address to receive an email when new articles are posted on . Tofacitinib demonstrates greater efficacy than placebo in adults with AS ...

Tofacitinib is an oral Janus kinase (JAK) inhibitor that has recently been approved for use in the treatment of rheumatoid arthritis. Clinical trials have identified increases in total cholesterol, ...

New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tofacitinib Global Market Report 2023" - https://www.reportlinker ...

Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans ...

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

Tofacitinib (tasocitinib, CP-690550), Pfizer’s novel Janus Kinase 3 (JAK) inhibitor for the treatment of rheumatoid arthritis (RA), had an anticipated FDA PDUFA (Prescription Drug User Fee Act) date ...